Abstract Details

Title Treatment Outcomes in People with Migraine Receiving Rimegepant or Triptans: A Descriptive Analysis from a Real-World Survey

Topic Headache

Presentation(s) P1 - Poster Session 1 (11:45 AM-12:45 PM)

Poster/Presentation
Number 12-008

Objective To assess treatment outcomes of people with migraine (PwM) who use rimegepant or triptans.

Background Triptan use is associated with clinical issues in some patients including cardiovascular contraindications, insufficient efficacy, and poor tolerability. Rimegepant is the only therapy approved for acute and preventive treatment of migraine. This descriptive analysis uses real-world data to assess treatment outcomes for patients receiving rimegepant or triptans.

Design/Methods Patient and physician data were drawn from the Adelphi Migraine Disease Specific Programme (DSP)™, a real-world, cross-sectional survey with retrospective data collection of physicians and their consulting adult PwM in the USA, conducted in 2022. Physicians provided treatment practice data for the next 10 consecutively consulting PwM, including migraine treatments, satisfaction, and consistency of treatment response over multiple attacks. Patients also provided data on response consistency and satisfaction, as well as treatment optimization (MTOQ score >24).

Results 91 rimegepant and 437 triptan users were included. Patient-reported data was available for 29 and 103 patients, respectively.

Physician-reported consistency (achieving pain freedom within 2 hours on more than half of occasions) was 73% for rimegepant users and 57% for triptan users. Patient-reported consistency of response (achieving pain freedom within 2 hours for 4 or 5 out of 5 attacks) was 76% and 63%, respectively.

For rimegepant, 95% of physicians and 97% of patients were satisfied with current acute treatment. For triptans, 87% of physicians and 78% of patients were satisfied. Furthermore, 59% of rimegepant users, and 22% of triptan users, reported being ‘extremely satisfied’.

Almost nine out of ten patients receiving rimegepant (87%) and 62% of patients receiving a triptan were optimized on treatment.

Conclusions Patients prescribed rimegepant monotherapy reported high satisfaction, response consistency, and treatment optimization. These data provide real-world evidence of the holistic value of rimegepant for the acute treatment of migraine.

Authors/Disclosures
Lucy Abraham (Pfizer R&D UK Ltd) PRESENTER	Lucy Abraham has received personal compensation for serving as an employee of Pfizer R&D UK Ltd. Lucy Abraham has stock in Pfizer R&D UK Ltd.
Joshua Brown, PhD (Pfizer, Inc.)	Dr. Brown has received personal compensation for serving as an employee of Pfizer, Inc..
Karin Hygge Blakeman	Karin Hygge Blakeman has received personal compensation for serving as an employee of Pfizer. Karin Hygge Blakeman has stock in Pfizer.
Feng Dai, PhD	Dr. Dai has received personal compensation for serving as an employee of Pfizer.
James Jackson (Adelphi Real World)	James Jackson has nothing to disclose.
William Whitton (Adelphi Real World)	William Whitton has received personal compensation for serving as an employee of Adelphi Real World.
Sophie Barlow	Miss Barlow has received personal compensation for serving as an employee of Adelphi Real World.
Lucy Hancock	Lucy Hancock has received personal compensation for serving as an employee of Adelphi Real World.

��ɫ��

��ɫ��